Uroplasty, Inc. showcased presentations, workshops and posters focusing on its solutions at the 34th Annual Meeting of the International Urogynecological Association (IUGA), June 16-20 in Como, Italy.
Urgent PC presentations at the IUGA annual meeting included following three studies:
“Peripheral Tibial Neurostimulation (PTNS) (Urgent PC) Versus Tolterodine (Detrusitol) In the Treatment Of Women With Urge Urinary Incontinence and Urge Symptoms,” presented by Oliver Preyer, M.D. of the Department of Obstetrics and Gynecology at the University of Vienna, Vienna, Austria, demonstrates Urgent PC has comparable performance to Tolterodine with a significantly lower rate of side effects.
“The Effects of Percutaneous Tibial Nerve Stimulation Therapy (Neuromodulation) On Quality Of Life Of Patients With Chronic Pelvic Pain,” was presented in a poster by S.G. Bayrak, M.D. of Istanbul University, Istanbul, Turkey, showing the treatment contributing to the quality of life of women with chronic pelvic pain by decreasing the intensity of pain (this indication is not approved in the US).
A presentation by Dr. Enrico Finazzi Agro of the Department of Urology at Tor Vergata University in Rome, Italy, featured a comparative effectiveness study of 35 patients treated by Uroplasty?s Urgent PC system or a placebo. The study titled “Percutaneous Tibial Nerve Stimulation (PTNS) Effects On Urge Incontinence Patients Are Not Caused By A Placebo Effect: A Double Blind, Placebo Controlled Study” found urgency and frequency decreased by more than 50 percent for 64.7 percent of patients treated with Urgent PC. No patients were considered to have responded to the placebo.
“The 2009 Annual IUGA Meeting represents a further accumulation of clinical evidence from leading physicians around the world supporting the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms often associated with overactive bladder,” said David Kaysen, President and CEO of Uroplasty, Inc. “As this clinical evidence continues to expand, we will be presenting this data to the medical directors of US payers as part of our effort to build awareness for reimbursement and eventually apply for a unique CPT code for PTNS here in the US. In addition to Urgent PC, Macroplastique, our ‘Gold Standard’ bulking agent for the treatment of adult female stress urinary incontinence, was highlighted in several podium and poster presentations and workshops.”
Uroplasty also sponsored a hands-on workshop where physician attendees were able to work with, and learn how to properly use, both Urgent PC and Macroplastique alongside physician experts in the use of the two products. This session drew a large audience of potential new users of both Urgent PC and Macroplastique and received positive reviews from the attendees.
“All in all, this 34th Annual IUGA Meeting was a significant success for Uroplasty,” concluded Mr. Kaysen. “Both Urgent PC and Macroplastique were highlighted in numerous venues which drove significant physician traffic to our exhibit booth generating a large number of sales leads for both our international and US businesses.”